Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools IDH-mutant glioma

IDH-mutant glioma

Programs, trials, and reported response and survival for IDH-mutant glioma.

Data as of 11.07.2026

IDH-mutant glioma

Response and survival, trial by trial.

Each card is one trial arm. A bar is a response percent the source states. Progression-free survival, overall survival, and a hazard ratio stay in the units the source used. This page does not subtract one arm from another.

1 arm has a reported figure in this set.

Vorasidenib 1

Vorasidenib

Vorasidenib 40 mg daily

40 mg · ITT

grade 2 IDH-mutant astrocytoma or oligodendroglioma after surgery only (n = 168 vs 163)

Comparator: placebo

PFS hazard ratio vs placebo (BIRC): 0.39 HR, primary analysis

time to next intervention hazard ratio: 0.26 HR, primary analysis

INDIGO · NCT04164901

A note on interpreting comparisons: this page lines up results from different trials so the broader evidence is visible. Treat a gap between arms as context. A randomized trial that assigns the treatments in the same study is the strongest comparison.